Abstract
Introduction: Neurosarcoidosis is a granulomatous disease of postulated immune aetiology. Novel effective therapies are required as this disease often progresses despite standard treatment with a combination of steroids and immunosuppressive agents. Infliximab is a chimeric monoclonal antibody that inactivates the pro-inflammatory cytokine tumor necrosis factor alpha. It has a potential role in the treatment of medically refractory neurosarcoidosis based on animal data and a number of case series.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
